GH Research (NASDAQ:GHRS) Shares Down 3.1%

Shares of GH Research PLC (NASDAQ:GHRS) dropped 3.1% during mid-day trading on Wednesday . The company traded as low as $10.54 and last traded at $10.65. Approximately 11,876 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 134,902 shares. The stock had previously closed at $10.99.

Analyst Upgrades and Downgrades

GHRS has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Monday, March 4th. JMP Securities reduced their target price on GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday, March 1st.

GH Research Trading Up 0.2 %

The firm has a 50-day simple moving average of $9.54 and a two-hundred day simple moving average of $7.79. The company has a market capitalization of $572.85 million, a price-to-earnings ratio of -16.16 and a beta of 0.84.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Equities research analysts anticipate that GH Research PLC will post -0.96 EPS for the current year.

Institutional Investors Weigh In On GH Research

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PEAK6 Investments LLC grew its position in GH Research by 72.9% during the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after purchasing an additional 16,991 shares during the period. Barclays PLC grew its position in shares of GH Research by 98.2% during the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after acquiring an additional 31,500 shares during the period. Lynx1 Capital Management LP grew its position in shares of GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after acquiring an additional 133,804 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of GH Research by 16.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock valued at $932,000 after acquiring an additional 12,911 shares during the period. Finally, RTW Investments LP grew its position in shares of GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after acquiring an additional 1,158,172 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.